A Simple Method for Generating Cerebral Organoids from Human Pluripotent Stem Cells

Yean Ju Hong*, So been Lee*, Joonhyuk Choi, Sang Hoon Yoon, Jeong Tae Do

Department of Stem Cell and Regenerative Biotechnology, KU Institute of Science and Technology, Konkuk University, Seoul, Korea

Background and Objectives: In recent years, brain organoid technologies have been the most innovative advance in neural differentiation research. In line with this, we optimized a method to establish cerebral organoids from feeder-free cultured human pluripotent stem cells. In this study, we focused on the consistent and robust production of cerebral organoids comprising neural progenitor cells and neurons. We propose an optimal protocol for cerebral organoid generation that is applicable to both human embryonic stem cells and human induced pluripotent stem cells.

Methods and Results: We investigated formation of neuroepithelium, neural tube, and neural folding by observing the morphology of embryoid bodies at each stage during the cerebral organoid differentiation process. Furthermore, we characterized the cerebral organoids via immunocytochemical staining of sectioned organoid samples, which were prepared using a Cryostat and Vibratome. Finally, we established a routine method to generate early cerebral organoids comprising a cortical layer and a neural progenitor zone.

Conclusions: We developed an optimized methodology for the generation of cerebral organoids using hESCs and hiPSCs. Using this protocol, consistent and efficient cerebral organoids could be obtained from hiPSCs as well as hESCs. Further, the morphology of brain organoids could be analyzed through 2D monitoring via immunostaining and tissue sectioning, or through 3D monitoring by whole tissue staining after clarification.

Keywords: Human pluripotent stem cells, Pluripotency, Differentiation, Organoid, Brain organoid

Introduction

Neural lineage differentiation in vitro using pluripotent stem cells (PSCs) has now progressed beyond the differentiation into simple neurons and glial cells, to the creation of organ-like tissues, or organoids (1-4). Human brain organoids contain various cell types such as neurons, glia, and microglia that constitute brain tissue, and their structure even resembles some regions of the actual human brain (5, 6). Therefore, brain organoids are the best tool to investigate the interaction between the neurons and supporting cells in the brain. The traditional two-dimensional (2D) cultures have limitations in mimicking the complexities of cell-cell interactions, 3D cell patterning, and cellular properties of the human brain (7-9). During the differentiation of PSCs, including human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), the differentiating cells are spatiotemporally self-assembled and spontaneously form natural tissue-like structures (7, 10).
was reported in 2001; the development of cerebral brain organoids from human PSCs was first reported in 2013 (5, 11). Lancaster et al. embedded the embryoid bodies committed to a neuroectodermal lineage into Matrigel droplets to induce 3D tissue growth and used a spinning bioreactor to evenly provide nutrients and gases during long-term culture (5, 12). Furthermore, Kadoshima et al. found that human ESC aggregates spontaneously formed dorsocaudal-ventrorostral axis with cortical tissues (13).

In the present study, we developed an optimized methodology for the generation of cerebral organoids using hESCs and hiPSCs, based on Lancaster’s protocol (12).

Materials and Methods

Cell cultures

For feeder-free cultures, hESCs (National Stem Cell Bank, Republic of Korea) and hiPSCs were cultured on a vitronectin-coated tissue culture dish in TeSR-E8 medium (Stem cell technologies, VBC, Canada). The PBS-diluted vitronectin (Thermo Fisher, MA, USA, 5 μg/ml) was added to the tissue culture dish and incubated at 37°C for 1 h. Cells were sub-cultured every 4~5 days in a 0.5 mM EDTA solution (Enzynomics, Daejeon, Republic of Korea), and 10 μM Y-27632 (Peprotech, Rocky Hill, USA) was added on the day of subculture.

Cerebral organoid generation from feeder-free cultured hPSCs

The cerebral organoid generation protocol was slightly modified from that reported previously (12), particularly in the early stages. The hESCs and hiPSCs were dissociated into small clumps with a 0.5 mM EDTA solution and plated on suspension dishes containing the Aggrewell EB formation medium (Stem Cell Technologies, VBC, Canada) and 10 μM Y-27632 for the first 2 days. The aggregated EBs were then washed every other day with TeSR-E8 medium supplemented with penicillin/streptomycin (Gibco, TX, USA). After 4 days, they were transferred to neural induction medium (DMEM/F12 [Gibco] supplemented with 1 : 100 N2 supplement [Gibco], 1% nonessential amino acids [Gibco], 1 × penicillin/streptomycin/glutamine [Gibco], and insulin 2.5 μg/ml). The EBs were then cultured in cerebral organoid maturation medium (a 1 : 1 mixture of DMEM/F12 [Gibco] and Neurobasal [Gibco] medium supplemented with 1 : 100 N2 supplement [Gibco], 1 : 50 B27 [Gibco] 1% nonessential amino acids [Gibco], 1 × penicillin/streptomycin/glutamine [Gibco], 2-mercaptoethanol 0.5 μM [Gibco], and insulin 2.5 μg/ml). The EBs were then cultured in cerebral organoid maturation medium until a transparent border was observed. The resulting EBs were then embedded into a Matrigel (BD biosciences) droplet on a parafilm sheet with dimples and incubated at 37°C for 40~60 min to solidify the Matrigel. The paraffilm sheets were removed, and the embedded EBs were cultured for 6 days in cerebral organoid differentiation medium (a 1 : 1 mixture of DMEM/F12 [Gibco] and Neurobasal [Gibco] medium supplemented with 1 : 200 N2 supplement [Gibco], 1 : 100 B27 without vitamin A [Gibco] 1% nonessential amino acids [Gibco], 1 × penicillin/streptomycin/glutamine [Gibco], 2-mercaptoethanol 0.5 μM [Gibco], and insulin 2.5 μg/ml). The EBs were then cultured in cerebral organoid maturation medium (a 1 : 1 mixture of DMEM/F12 [Gibco] and Neurobasal [Gibco] medium supplemented with 1 : 100 N2 supplement [Gibco], 1 : 50 B27 [Gibco] 1% nonessential amino acids [Gibco], 1 × penicillin/streptomycin/glutamine [Gibco], 2-mercaptoethanol 0.5 μM [Gibco], and insulin 2.5 μg/ml). The detailed sequence of hESC differentiation and the culture of cerebral organoids is described in the Results section.

Microsection and immunocytochemistry

The cerebral organoids tissues were fixed with 4% paraformaldehyde (Sigma, St. Louis, MO, USA) for 2 h at 4°C. For cryosectioning, the organoids were incubated in a 30% sucrose solution in PBS for 2 days at 4°C until they sink. Tissues were then embedded in OCT compound (Tissue-Tek) and frozen at −80°C. A Cryotome (Leica, CM-1850) was used for preparing sections, and tissues were sectioned at −25°C with 20 μm thickness. After sectioning, the tissues were washed with PBS (Gibco) for 30 min to eliminate the residual OCT compound. For vibratome sectioning, the fixed organoids were embedded in 3% agarose gel. Slicing was performed using a 7000 SMZ vibratome (Campden) in PBS at 0.3 mm/s speed, 1.00 mm amplitude, and 50Hz. Then, 50~100 μm cerebral organoid slices were peeled off at a time from the sample and gathered using a small art brush. The sectioned tissues were treated with PBS, containing 3% bovine serum albumin and 0.03% Triton X-100 (Sigma), for 45 min at 20~25°C.

The adherent cells were fixed with 4% paraformaldehyde (Sigma) for 20 min at 4°C. After washing with PBS (Gibco), the cells were treated with PBS, containing 3% bovine serum albumin and 0.03% Triton X-100 (Sigma), for 45 min at 20~25°C.

For 3D immunocytochemistry, cerebral organoids were fixed with 4% paraformaldehyde (Sigma) for 1 day at 4°C. After washing with PBS (Gibco), the tissues were treated with PBS, containing 6% bovine serum albumin and 0.03% Triton X-100 (Sigma), for 1 day at 20~25°C.

Primary antibodies and fluorescence-labeled secondary antibodies were used according to the manufacturer’s specifications. The primary antibodies used were anti-OCT4 (OCT4; polyclonal, 1 : 500, Santacruz), anti-TRA-1-81 (TRA-1-81; polyclonal, 1 : 500, Santacruz), and anti-α-smooth muscle actin (α-SMA; monoclonal, 1 : 50, Sigma). The secondary antibodies used were Alexa Fluor 488 (1 : 500, Life technology) and Alexa Fluor 555 (1 : 500, Life technology).
Fig. 1. Characterization of human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs). (A) Phase contrast images of hESCs and hiPSCs in feeder-free conditions. Scale bar=200 μm. (B) Immunocytochemical staining of the pluripotency markers OCT4, SOX2, and TRA-1-81 in hESCs (upper) and hiPSCs (lower). Scale bar=200 μm in the upper panels and 100 μm in the lower panels. (C) Growth rate of hESCs from 2 to 4 days after seeding. Growth rate was measured as an increase in colony size (μm²). Error bars represent standard error of the mean.
Fig. 2. Brain organoid differentiation protocol using human pluripotent stem cells (hPSCs). (A) Schematic illustration of the generation of brain organoids. Representative images characterizing each stage are shown. Scale bar=200 μm. (B) Morphology of embryoid bodies (EBs) in EB formation medium, based on TeSR medium (upper left), and their enlarged images (upper right). EBs committed to the neural lineage showed a transparent neuroepithelium-like region at the periphery of the structure (lower left), which is depicted with a white dotted circle (lower right). Scale bar=500 μm (lower left), 200 μm (lower right). (C) Comparison of koSR-containing medium (hESC medium) and Aggrewell EB medium for the size of EBs differentiated from hESCs. Scale bars=200 μm.

Embedding of EBs into Matrigel and subsequent culture for cerebral organoid formation

To use Matrigel, it must be liquefied at 4°C by refrigerating one day before use. After washing with fresh medium, EBs with a transparent border were selected and embedded in Matrigel droplets on a dimpled parafilm sheet (Fig. 3A) (12). Matrigel containing EBs was then solidified at 37°C for about 40–60 min in an incubator. After solidification, the EB-containing Matrigel was transferred into a Petri dish and cerebral organoid differentiation medium was added. If a lot more organoid samples were required, embedding was performed in a different manner (Fig. 3A). First, 150 μl of liquefied Matrigel was spread in a 4-well dish and cerebral organoid differentiation medium was added. If a lot more organoid samples were required, embedding was performed in a different manner (Fig. 3A). First, 150 μl of liquefied Matrigel was spread in a 4-well dish and cerebral organoid differentiation medium was added. If a lot more organoid samples were required, embedding was performed in a different manner (Fig. 3A). First, 150 μl of liquefied Matrigel was spread in a 4-well dish and cerebral organoid differentiation medium was added. If a lot more organoid samples were required, embedding was performed in a different manner (Fig. 3A).
cerebral organoids through a neural folding process.

The major limitation of the current brain organoid culture methods is the apoptosis or necrotic body formation in the internal parts as organoids grow in size during long-term culture. In the living body, the vascular system is spread throughout the organs to provide a continuous supply of oxygen and nutrients to the deeper parts of the body. However, in vitro organoid culture systems cannot supply oxygen and nutrients to the internal parts of organoids due to a lack of vascular formation. To address this problem, many laboratories use an agitation culture system, or attempt to culture organoids as small pieces (5, 14-16). To develop a cost-effective method for organoid culture, we used a magnetic spin culture system (Fig. 3A). On day 6 after embedding in Matrigel, cerebral organoids were transferred into a 24-well dish containing 2 ml cerebral organoid maturation medium, with a mini magnetic bar at the bottom of each well. Each mini magnetic bar can be controlled independently by using 2mag Magnetic stirrer (Germany). Using magnetic spin culture system, 24 organoids can be individually cultured in each well of a 24-well dish. Although the Matrigel surrounding the organoid is slightly damaged by the rotating magnetic spin bar, this system is sufficient for culturing the organoids up to 2∼3 mm in diameter. For up to 40 days, cerebral organoids can be cultured in a non-rotating system. However, spin culture system could be effective for long-term culture, as internal necrosis usually begins to occur at approximately 30∼40 days of organoid culture (from EB formation).

**Characterization of cerebral organoids**

Approximately 30 days after embedding in Matrigel, the cerebral organoids showed typical characteristics, such as a folded neuroepithelium-like surface, a large number of rosette structures, and formation of ventricular zones. Thus, the normal formation of early cerebral organoids could be confirmed via light microscopy, through which the following features were checked: 1) a folded structure on the outer surface, 2) vertically arranged cells in neuroepithelium-like region, and 3) the existence of rosettes and ventricular structures in the interior (Fig. 3C). To confirm the normal formation of cerebral organoids, further analyses are required. We determined whether the organoids were composed of neural lineage cells, and which part of the brain tissue they were close to. Transcriptome analysis only shows whether cerebral organoids contain neural lineage cells. Therefore, to determine how closely organoids mimic the brain structure, immunocytochemistry analysis is an essential approach for organoid characterization. The detailed structure of cerebral organoids can be observed in 2D and 3D images using confocal microscopy. To obtain 2D images, sectioned tissues were immunostained with several neural markers, and images were then captured using a confocal microscope (Fig. 4A). To section organoid tissues, two methods were used: cryosectioning
Fig. 4. Characterization of human embryonic stem cell (hESC)- and human induced pluripotent stem cell (hiPSC)-derived brain organoids. (A) 2D immunocytochemistry staining of the early neuron marker TUJ-1 and the neural progenitor marker SOX2 in hPSC-derived organoids. A Cryostat (upper) and Vibratome (lower) were used for tissue sectioning. Scale bar=100 μm (upper panels) and 200 μm (lower panels). Green arrow indicates cortical plate, red arrow indicates ventricular zone, and white arrow indicates ventricle (Cryostat sample). Green arrow indicates ventricular zone, red arrow indicates cortical plate, and white arrow indicates ventricle (Vibratome sample). (B) Confocal images of 3D immunocytochemistry for the early neuron marker TUJ-1 and the neural progenitor marker SOX2 in hESC- and hiPSC-derived organoids. Scale bar=50 μm (upper panels) and 20 μm (lower panels). (C) Representative 3D image of whole brain organoids, which were stained with TUJ-1 and SOX2 (at day 12 hESC-derived). The image was captured using high contents screening (HCS). Scale bars=200 μm.
and vibratome sectioning. Both methods have their pros and cons; cryosectioning using a cryostat can cut tissues to a thickness of 20 μm whereas the lowest section thickness that a vibratome can reliably achieve is approximately 50 μm. However, cryostat-cut sections often show tissue tearing, whereas vibratome sections are relatively defect-free. When images are acquired using a confocal microscope, this slight difference in thickness does not affect the image. Thus, vibratome sectioning is recommended because this method does not require dehydration and freezing and causes less tissue damage. To obtain 3D images, CLARITY is required for tissue clarification to make the tissue transparent before immunostaining the cerebral organoids using the clearing solution (17, 18). The 3D images can reveal the overall shape and structure of a whole organoid, whereas 2D images can provide the precise structure of the internal regions of organoids. Therefore, we recommend performing both 2D and 3D image analyses to accurately identify the characteristics of the organoids. As the hierarchical arrangement of different cell types in cerebral organoids is the most prominent feature of the cerebral cortex, we stained both a progenitor marker (SOX2) and neuronal markers (TUJ1) in the same sample. We could observe a ventricular zone (VZ), and a cortical plate (CP) with developing neurons (Fig. 4A and 4B) in the hESC-derived cerebral organoid. The hiPSC-derived cerebral organoid showed a relatively indistinct layer distribution; however, vertically arranged oval-shaped cells co-expressing SOX2 and TUJ-1 were present in the neuroepithelium-like region, which may represent the neural progenitors differentiating into neurons. The cortical regions of hiPSC-derived cerebral organoids appear to be relatively immature and may require further cultivation for neuronal differentiation (Fig. 4B). In general, hiPSCs are differentiated more slowly than hESCs. Further, the differentiation rate may vary slightly from cell line to cell line; thus, the duration of each organoid differentiation stage should be adjusted according to the cell lines and their status. Most cells constituting the 30-day-old brain organoids are neurons and neural stem cells, and there are almost no glial cells, such as astrocytes and oligodendrocytes. This is because glial specification in brain organoids usually occurs after culture for more than 100 days (19, 20).

Discussion

Recently, with the success of clinical studies and cell therapy application cases using iPSCs (21), the clinical applicability of iPSC-derived brain organoid has increased. To take one step closer to clinical application or drug screening using hiPSC-derived organoids, an efficient protocol that can be applied to various types of patient-derived iPSCs is needed. To date, the routine formation of brain organoids using hPSCs with a single standardized protocol has not been reported. This is because each hPSC line displays different properties and, sometimes, even the same cell line shows a different cell state at the time of differentiation. Cells are sensitive to the environment depending on subculture density, experimental skills, and incubation condition. Therefore, the protocol presented in this study may need to be modified to suit each laboratory even if the same hPSC line is used. For cerebral organoid production, a thorough control of these variables is needed to maintain the optimal state of hPSCs. Furthermore, it is necessary to minimize heterogeneity during the subsequent differentiation process. Accordingly, we attempted to develop an optimal differentiation protocol for generating cerebral organoids with minimal protocol changes between using hESCs as well as hiPSCs. We shortened the EB formation time and enhanced EB formation efficiency using an aggregation-promoting medium. Cerebral organoid differentiation begins with cell clumps, as they are prone to death when treated as single cells. Thus, cell numbers need to be adjusted to form EBs with a uniform size as the different cell numbers can make large difference in the size of EBs, which cause heterogeneity in each cerebral organoid. When homogenous organoids are used for drug screening, it is possible to reduce the error in the effect of the treated drug. Another important issue to consider is the complete removal of undifferentiated cells and cells of other lineage. For this, dual SMAD inhibition, which blocks differentiation into the mesoderm and endoderm, may be applied at the beginning of hPSCs differentiation, or a method using human neural progenitor cells (hNPCs) other than hPSCs could also be considered (14, 22, 23). To eliminate undifferentiated cells from the differentiating/differentiated population, fluorescence activated cell sorting after PSC-specific surface maker staining is feasible. A recent study used quercetin to selectively remove undifferentiated cells with 99.99% efficiency; this method can also be applied clinically (24). Further, necrosis at the center of maturing brain organoids is a major challenge that limits long-term culture and further applications. A live section method could be one of the solutions to increase the survival rate and maturity of the organoids, enabling their long-term culture (16). By using vibrating microtomes, such as the Vibratome or Compressome, live organoids could be divided into small pieces, with the same thickness, that maintain their viability and
maturity with minimum damage. These sectioned organoid fragments can be recultivated for the further maturation of organoids, and some of these fragments can be used for quality control and characterization.

One of the obstacles in brain organoid generation is the delayed glial specification during brain organoids formation, which may limit the value and clinical applicability of brain organoids, as it usually takes more than 100 days (19, 20). However, recent studies have suggested methods to promote glial and microglial differentiation within cerebral organoids. Shaker et al. developed a protocol to generate human brain organoids containing oligodendrocytes, within 42 days of differentiation. The cocktail of growth factors and small molecules, including thyroid hormone T3, neurotrophin NT3, hepatocyte growth factor, insulin growth factor and platelet-derived growth factor, could drive the differentiation of oligodendroglial lineage in brain organoids (25). Furthermore, Ormel et al. (26) found that microglia-like cells, which were derived from the mesoderm lineage, were present in cerebral organoids. The microglial marker IBA-1 was examined from as early as day 24 of differentiation and IBA-1+ cells were localized throughout the organoids at later stage.

Ultimately, the generated brain organoids should have uniform properties and functionality that meets the minimum standards; the general criteria for determining qualified brain organoids should also be established. As many researchers investigate this topic intensively, brain organoids could be a promising source for drug screening and tissue replacement therapy using the patient’s own 3D brain structure.

Acknowledgments

This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (grant nos. 2016M3A9B6946835, 2015R1A5A1009701, and 2020R1A2C3007562) and Korea Disease Control and Prevention Agency (grant no. 2018ER610400) of the Republic of Korea. This paper was also supported by Konkuk University Researcher Fund in 2021.

Potential Conflict of Interest

The authors have no conflicting financial interest.

References

1. Fatehullah A, Tan SH, Barker N. Organoids as an in vitro model of human development and disease. Nat Cell Biol 2016;18:246-254
2. Kelava I, Lancaster MA. Dishing out mini-brains: current progress and future prospects in brain organoid research. Dev Biol 2016;420:199-209
3. Di Lullo E, Kriegstein AR. The use of brain organoids to investigate neural development and disease. Nat Rev Neurosci 2017;18:573-584
4. Quadrato G, Arlotta P. Present and future of modeling human brain development in 3D organoids. Curr Opin Cell Biol 2017;49:47-52
5. Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurles ME, Homfray T, Penninger JM, Jackson AP, Knoblich JA. Cerebral organoids model human brain development and microcephaly. Nature 2013;501:373-379
6. Quadrato G, Nguyen T, Macosko EZ, Sherwood JL, Min Yang S, Berger DR, Maria N, Scholvin J, Goldman M, Kinney JP, Boyden ES, Lichtman JW, Williams ZM, McCarro SA, Arlotta P. Cell diversity and network dynamics in photosensitive brain human organoids. Nature 2017;545:48-53
7. Qian X, Song H, Ming GL. Brain organoids: advances, applications and challenges. Development 2019;146:dev166074
8. Nam KH, Yi SA, Jang HJ, Han JW, Lee J. In vitro modeling for inherited neurological diseases using induced pluripotent stem cells: from 2D to organoid. Arch Pharm Res 2020;43:877-889
9. Koo B, Choi B, Park H, Yoon K, Past, present, and future of brain organoid technology. Mol Cells 2019;42:617-627
10. Hong YJ, Do JT. Neural lineage differentiation from pluripotent stem cells to mimic human brain tissues. Front Bioeng Biotechnol 2019;7:400
11. Zhang SC, Wernig M, Duncan ID, Brüstle O, Thomson JA. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol 2001;19: 1129-1133
12. Lancaster MA, Knoblich JA. Generation of cerebral organoids from human pluripotent stem cells. Nat Protoc 2014;9: 2329-2340
13. Kadoshima T, Sakaguchi H, Nakano T, Soen M, Ando S, Eiraku M, Sasai Y. Self-organization of axial polarity, inside-out layer pattern, and species-specific progenitor dynamics in human ES cell-derived neocortex. Proc Natl Acad Sci U S A 2013;110:20284-20289 Erratum in: Proc Natl Acad Sci U S A 2014;111:7498
14. Qian X, Nguyen HN, Song MM, Hadjicou C, Ogden SC, Hammack C, Yao B, Hamersky GR, Jacob F, Zhong C, Yoon KJ, Jeang W, Lin L, Li Y, Thakor J, Berg DA, Zhang C, Kang E, Chickering M, Nauen D, Ho CY, Wenz L, Christian KM, Shi PY, Maher BJ, Wu H, Jin P, Tang H, Song H, Ming GL. Brain-region-specific organoids using mini-bioreactors for modeling ZIKV exposure. Cell 2016;165:1238-1254
15. Giandomenico SL, Sutcliffe M, Lancaster MA. Generation and long-term culture of advanced cerebral organoids for studying later stages of neural development. Nat Protoc
16. Qian X, Su Y, Adam CD, Deutschmann AU, Pather SR, Goldberg EM, Su K, Li S, Lu L, Jacob F, Nguyen PTT, Huh S, Hoke A, Swinford-Jackson SE, Wen Z, Gu X, Pierce RC, Wu H, Briand LA, Chen HJ, Wolf JA, Song H, Ming GL. Sliced human cortical organoids for modeling distinct cortical layer formation. Cell Stem Cell 2020;26:766-781.e9

17. Chung K, Deisseroth K. CLARITY for mapping the nervous system. Nat Methods 2013;10:508-513 Erratum in: Nat Methods 2013;10:1035

18. Azaripour A, Lagerweij T, Scharfbillig C, Jadczak AE, Willershausen B, Van Noorden CJ. A survey of clearing techniques for 3D imaging of tissues with special reference to connective tissue. Prog Histochem Cytochem 2016;51:9-23

19. Sloan SA, Darmanis S, Huber N, Khan TA, Brey F, Caneda C, Reimer R, Quake SR, Barres BA, Pașca SP. Human astrocyte maturation captured in 3D cerebral cortical spheroids derived from pluripotent stem cells. Neuron 2017;95:779-790.e6

20. Marton RM, Miura Y, Sloan SA, Li Q, Revah O, Levy RJ, Huguenard JR, Pașca SP. Differentiation and maturation of oligodendrocytes in human three-dimensional neural cultures. Nat Neurosci 2019;22:484-491

21. Schweitzer JS, Song B, Herrington TM, Park TY, Lee N, Ko S, Jeon J, Cha Y, Kim K, Li Q, Henschcliffe C, Kaplitt M, Nef C, Rapalino O, Seo H, Lee IH, Kim J, Kim T, Petsko GA, Ritz J, Cohen BM, Kong SW, Leblanc P, Carter BS, Kim KS. Personalized iPSC-derived dopamine progenitor cells for Parkinson's disease. N Engl J Med 2020;382:1926-1932

22. Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPSC cells by dual inhibition of SMAD signaling. Nat Biotechnol 2009;27:275-280 Erratum in: Nat Biotechnol 2009;27:485

23. Monzel AS, Smits LM, Hemmer K, Hachi S, Moreno EL, van Wuellen T, Jarazo J, Walter J, Brüggemann I, Boussaad I, Berger E, Fleming RMT, Bolognin S, Schwamborn JC. Derivation of human midbrain-specific organoids from neuroepithelial stem cells. Stem Cell Reports 2017;8:1144-1154

24. Song B, Cha Y, Ko S, Jeon J, Lee N, Seo H, Park KJ, Lee IH, Lopes C, Feitosa M, Luna MJ, Jung JH, Kim J, Hwang D, Cohen BM, Teicher MH, Leblanc P, Carter BS, Kordower JH, Bolshakov VY, Kong SW, Schweitzer JS, Kim KS. Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson's disease models. J Clin Invest 2020;130:904-920

25. Shaker MR, Pietrogrande G, Martin S, Lee JH, Sun W, Wolvetang EJ. Rapid and efficient generation of myelinating human oligodendrocytes in organoids. Front Cell Neurosci 2021;15:631548

26. Ormel PR, Vieira de Sá R, van Bodegraven EJ, Karst H, Harschnitz O, Sneeboer MAM, Johansen LE, van Dijk RE, Schepfels H, Berdenis van Berlekom A, Ribes Martínez E, Kling S, MacGillavry HD, van den Berg LH, Kahn RS, Hol EM, de Witte LD, Pasterkamp RJ. Microglia innately develop within cerebral organoids. Nat Commun 2018;9:4167